![The Economics of “Delinking” PBM Compensation](https://getmga.com/wp-content/uploads/2023/11/iStock-878855074-e1698884939416-1080x675.jpg)
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.